Literatur
- 1
Braun J, Bollow M, Eggens U, König H, Distler A, Sieper J.
Use of dynamic magnetic resonance imaging with fast imaging in the detection of early
and advanced sacroiliitis in spondylarthropathy patients.
Arthritis Rheum.
1994;
37
1039-1045
- 2
Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A. et al .
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.
Arthritis Rheum.
1998;
41
58-67
- 3
Braun J, Bollow M, Seyrekbasan F, Haberle H J, Eggens U, Mertz A, Distler A, Sieper J.
Computed tomography guided corticosteroid injection of the sacroiliac joint in patients
with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic
magnetic resonance imaging.
J Rheumatol.
1996;
23
659-664
- 4
Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H,
Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J.
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled
multicentre trial.
Lancet.
2002;
359
1187-1193
- 5
Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D.
ASAS Working Group .
International ASAS consensus statement for the use of anti-tumour necrosis factor
agents in patients with ankylosing spondylitis.
Ann Rheum Dis.
2003;
62
817-824
- 6
Davis J C, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg D O, Kivitz A, Fleischmann R,
Inman R, Tsuji W. Enbrel Ankylosing Spondylitis Study Group .
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing
spondylitis: a randomized, controlled trial.
Arthritis Rheum.
2003;
48
3230-3236
- 7
Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J.
Conventional treatments for ankylosing spondylitis (Review).
Ann Rheum Dis.
2002;
61
(Suppl 3)
iii40-50
- 8
Haibel H, Rudwaleit M, Braun J, Sieper J.
Six months open label trial of leflunomide in active ankylosing spondylitis.
Ann Rheum Dis.
2005;
64
124-126
- 9
Märker-Hermann E, Sieper J, Zeidler H.
Spondyloarthritiden - neue Aspekte zur Klassifikation, Diagnostik und Therapie.
Dtsch Med Wochenschr.
2004;
129
1328-1334
- 10
Rudwaleit M, Khan M A, Sieper J.
The challenge of diagnosis and classification in early ankylosing spondylitis: do
we need new criteria?.
Arthritis Rheum.
2005;
52
1000-1008
- 11
Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha
blockers in ankylosing spondylitis.
Ann Rheum Dis.
2004;
63
665-670
- 12
Rudwaleit M, Sieper J.
Diagnose und Frühdiagnose der ankylosierenden Spondylitis (Morbus Bechterew).
Z Rheumatol.
2004;
63
193-202
- 13
Rudwaleit M, van der Heijde D, Khan M A, Braun J, Sieper J.
How to diagnose axial spondyloarthritis early?.
Ann Rheum Dis.
2004;
63
535-543
- 14
Sieper J, Rudwaleit M.
Early referral recommendations for axial spondyloarthritis (including pre-radiographic
and radiographic ankylosing spondylitis) in primary care.
Ann Rheum Dis.
2005;
64
659-663
- 15
Van der Linden S, Valkenburg H A, Cats A.
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification
of the New York criteria.
Arthritis Rheum.
1984;
27
361-368
- 16
Falkenbach A.
Radontherapie des Morbus Bechterew: Nutzen und Risiko.
Dtsch Med Wochenschr.
2001;
126
1379-1380
Priv.-Doz. Dr. Martin Rudwaleit
Charité Universitätsmedizin, Campus Benjamin Franklin, Med. Klinik I - Rheumatologie
Hindenburgdamm 30
12200 Berlin
Phone: 030/84454547
Fax: 030/84454582
Email: martin.rudwaleit@charite.de
